On August 16, 2022, the former President Biden signed into law the Inflation Reduction Act that includes a provision that is intended to lower certain prescription drug costs under Medicare.
All entries for: Oncology
April 1, 2026
Genenta Science S.p.A.
Neutral Outlook
Milan, Lombardy
51-200 employees
Thus, while it is unclear how the IRA will be fully implemented, it will likely have a significant impact on the biopharmaceutical industry and the pricing of prescription drug products.
Disease Area: Oncology
Drug Type: Biologic
March 31, 2026
Neonc Technologies Holdings, Inc/CA
Neutral Outlook
Calabasas, CA
1-50 employees
In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the IRA) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program.
Disease Area: Neurological Diseases, Oncology
Drug Type: Small Molecule
March 31, 2026
OS Therapies Inc
Neutral Outlook
Grasonville, MD
1-50 employees
Healthcare reform legislation also influences coverage, pricing and reimbursement for biopharmaceutical products. In the United States, statutes such as the Affordable Care Act and the Inflation Reduction Act, as well as other federal and state programs, establish requirements for Medicaid and Medicare drug rebates, coverage determinations, pricing transparency and other programmatic matters.
Disease Area: Oncology
Drug Type: Biologic
March 31, 2026
Kairos Pharma, LTD
Neutral Outlook
Los Angeles, CA
1-50 employees
In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the IRA) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program.
Disease Area: Oncology
Drug Type: Small Molecule
March 31, 2026
OSR Holdings, Inc
Negative Outlook
Bellevue, WA
1-50 employees
The Affordable Care Act and the Inflation Reduction Act, as well as other ongoing healthcare legislative and regulatory reform measures, may have a material adverse effect on our business and results of operations.
Disease Area: Oncology
Drug Type: Biologic
March 31, 2026
Nanobiotoix S.A.
Negative Outlook
Paris, France
51-200 employees
Additionally, in the United States, the Inflation Reduction Act of 2022 (IRA), enacted on August 16, 2022, includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government. We cannot predict the ultimate content, timing or effect of any changes to the ACA, the IRA or other federal and state reform efforts, and there can be no assurance that any such health care reforms will not adversely affect our future business and financial results.
Disease Area: Oncology
Drug Type: Biologic
March 31, 2026
Tevogen Bio Holdings Inc
Neutral Outlook
Warren, NJ
51-200 employees
For example, the Inflation Reduction Act introduces several changes to the Medicare Part D benefit, including a limit on annual out-of-pocket costs and a change in manufacturer liability under the program which could negatively affect the profitability of our product candidates. The IRA sunsets the current Part D coverage gap discount program starting in 2025 and replaces it with a new manufacturer discount program. Failure to pay a discount under this new program will be subject to a civil monetary penalty. In addition, the IRA established a Medicare Part B inflation rebate scheme effective January 2023 and a Medicare Part D inflation rebate scheme effective October 2022, under which, generally speaking, manufacturers will owe rebates if the price of a Part B or Part D drug increases faster than the pace of inflation.
Disease Area: Infectious Diseases, Oncology
Drug Type: Multiple